-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CAR20.19.22 T-cells in T-Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CAR20.19.22 T-cells in T-Cell Lymphomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CAR20.19.22 T-cells in T-Cell Lymphomas Drug Details: Gene-modified cell therapy...
-
Product Insights
NewB And T Lymphocyte Attenuator – Drugs In Development, 2024
The B And T Lymphocyte Attenuator pipeline drugs market research report outlays comprehensive information on the B And T Lymphocyte Attenuator targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Immunology, Oncology, and Dermatology which include indications of Graft Versus Host Disease (GVHD), Autoimmune Disorders, Solid Tumor, Renal Cell Carcinoma, and Atopic Dermatitis (Atopic Eczema). It also reviews...
-
Product Insights
NewInducible T Cell Costimulator – Drugs In Development, 2024
The Inducible T Cell Costimulator pipeline drugs market research report outlays comprehensive information on the Inducible T Cell Costimulator targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Immunology, Metabolic Disorders, and Ophthalmology which include indications of Non-Small Cell Lung Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Systemic Lupus Erythematosus, Type 1 Diabetes (Juvenile Diabetes), and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Linperlisib in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Linperlisib in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Linperlisib in T-Cell Acute Lymphocytic...
-
Product Insights
NewCytotoxic T Lymphocyte Protein 4 – Drugs In Development, 2024
The Cytotoxic T Lymphocyte Protein 4 pipeline drugs market research report outlays comprehensive information on the Cytotoxic T Lymphocyte Protein 4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Immunology, Infectious Disease, and Genetic Disorders which include indications of Solid Tumor, Non-Small Cell Lung Cancer, Rheumatoid Arthritis, Graft Versus Host Disease (GVHD), Epstein–Barr Virus (HHV-4) Infections,...
-
Product Insights
NewT Lymphocyte Activation Antigen CD86 – Drugs In Development, 2024
The T Lymphocyte Activation Antigen CD86 pipeline drugs market research report outlays comprehensive information on the T Lymphocyte Activation Antigen CD86 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Immunology, Infectious Disease, Oncology, and Central Nervous System which include indications of Rheumatoid Arthritis, Graft Versus Host Disease (GVHD), Infectious Disease, Coronavirus Disease 2019 (COVID-19), Oncology, Melanoma, Alzheimer's...
-
Product Insights
NewT Cell Surface Glycoprotein CD4 – Drugs In Development, 2024
The T Cell Surface Glycoprotein CD4 pipeline drugs market research report outlays comprehensive information on the T Cell Surface Glycoprotein CD4 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Infectious Disease, Immunology, Respiratory, and Central Nervous System which include indications of Human Immunodeficiency Virus (HIV) Infections (AIDS), Graft Versus Host Disease (GVHD), Immunology, Asthma, and Chronic Inflammatory...
-
Product Insights
NewT Lymphocyte Activation Antigen CD80 – Drugs In Development, 2024
The T Lymphocyte Activation Antigen CD80 pipeline drugs market research report outlays comprehensive information on the T Lymphocyte Activation Antigen CD80 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Immunology, Metabolic Disorders, and Central Nervous System which include indications of Solid Tumor, Gastric Cancer, Rheumatoid Arthritis, Graft Versus Host Disease (GVHD), Type 1 Diabetes (Juvenile Diabetes),...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RD-1302 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RD-1302 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RD-1302 in T-Cell Acute Lymphocytic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BEAM-201 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BEAM-201 in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BEAM-201 in T-Cell Acute Lymphocytic...